Ameren (AEE) Touches $57.20 High on Aug, 4; Impax Laboratories (IPXL) Sentiment Is 1.18

August 4, 2017 - By Vivian Currie

Impax Laboratories, Inc. is a specialty pharmaceutical company. The company has market cap of $1.22 billion. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , in addition to the development and marketing of branded products. It currently has negative earnings. The Company’s divisions include Impax Generics and Impax Specialty Pharma.

The stock of Ameren Corp (NYSE:AEE) reached all time high today, Aug, 4 and still has $60.63 target or 6.00% above today’s $57.20 share price. This indicates more upside for the $13.88B company. This technical setup was reported by Barchart.com. If the $60.63 PT is reached, the company will be worth $832.80 million more. About 422,301 shares traded. Ameren Corp (NYSE:AEE) has risen 17.42% since August 4, 2016 and is uptrending. It has outperformed by 0.72% the S&P500.

Since February 28, 2017, it had 0 insider buys, and 5 sales for $1.05 million activity. Shares for $71,702 were sold by LYONS MARTIN J on Tuesday, February 28. NELSON GREGORY L sold $99,641 worth of stock or 1,834 shares. BAXTER WARNER L sold $748,421 worth of stock or 13,310 shares. 1,392 shares valued at $75,600 were sold by Steinke Bruce A on Tuesday, February 28. Lindgren Mark C also sold $55,542 worth of Ameren Corp (NYSE:AEE) on Tuesday, February 28.

Investors sentiment decreased to 0.99 in 2016 Q4. Its down 0.07, from 1.06 in 2016Q3. It worsened, as 34 investors sold Ameren Corp shares while 161 reduced holdings. 61 funds opened positions while 132 raised stakes. 166.27 million shares or 4.87% more from 158.55 million shares in 2016Q3 were reported. 368,354 are owned by State Board Of Administration Of Florida Retirement Systems. Capstone Asset Management Company has invested 0.05% of its portfolio in Ameren Corp (NYSE:AEE). The New York-based Neuberger Berman Limited Liability Corp has invested 0.09% in Ameren Corp (NYSE:AEE). First Interstate National Bank & Trust invested in 0.01% or 1,056 shares. Ferguson Wellman Capital Mngmt reported 181,897 shares or 0.39% of all its holdings. C M Bidwell Associate Ltd has 0.05% invested in Ameren Corp (NYSE:AEE). Brandywine Glob Investment Management Ltd Com accumulated 216,851 shares or 0.07% of the stock. Hbk Invs Ltd Partnership has 148,800 shares for 0.08% of their portfolio. State Street Corp invested 0.06% in Ameren Corp (NYSE:AEE). Los Angeles Mgmt Equity Rech Inc, California-based fund reported 221,665 shares. Lsv Asset Mngmt stated it has 1.22M shares or 0.12% of all its holdings. First Republic Inv Mngmt Inc holds 0.01% of its portfolio in Ameren Corp (NYSE:AEE) for 14,078 shares. Johnson Grp invested in 0.01% or 1,152 shares. Macquarie Group stated it has 0.01% of its portfolio in Ameren Corp (NYSE:AEE). Bnp Paribas Arbitrage Sa has 91,137 shares.

Among 5 analysts covering Ameren (NYSE:AEE), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. Ameren has $55 highest and $45 lowest target. $48.75’s average target is -14.77% below currents $57.2 stock price. Ameren had 13 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Ameren Corp (NYSE:AEE) earned “Outperform” rating by Wolfe Research on Monday, August 3. The company was maintained on Monday, May 16 by Barclays Capital. The stock of Ameren Corp (NYSE:AEE) has “Hold” rating given on Tuesday, August 25 by Zacks. The firm has “Neutral” rating given on Tuesday, July 28 by Goldman Sachs. As per Monday, April 4, the company rating was downgraded by Argus Research. The rating was downgraded by Barclays Capital to “Equal-Weight” on Thursday, May 25. Barclays Capital upgraded the shares of AEE in report on Monday, April 4 to “Overweight” rating. UBS maintained Ameren Corp (NYSE:AEE) on Wednesday, October 19 with “Neutral” rating. The company was downgraded on Monday, June 26 by Goldman Sachs. The rating was maintained by Argus Research on Monday, August 24 with “Buy”.

Ameren Corporation is a utility holding company. The company has market cap of $13.88 billion. The Company’s subsidiaries include Ameren Missouri, Ameren Illinois and Ameren Transmission Company . It has a 21.37 P/E ratio. It operates through four divisions.

About 678,227 shares traded. Impax Laboratories Inc (IPXL) has declined 49.01% since August 4, 2016 and is downtrending. It has underperformed by 65.71% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 3 sales for $43,046 activity.

Ratings analysis reveals 0 of Impax Labs’s analysts are positive. Out of 5 Wall Street analysts rating Impax Labs, 0 give it “Buy”, 1 “Sell” rating, while 4 recommend “Hold”. The lowest target is $15.0 while the high is $18.0. The stock’s average target of $17 is 3.03% above today’s ($16.5) share price. IPXL was included in 5 notes of analysts from September 27, 2016. The rating was upgraded by Goldman Sachs on Tuesday, September 27 to “Neutral”. RBC Capital Markets maintained the shares of IPXL in report on Thursday, November 10 with “Sector Perform” rating. The rating was downgraded by WallachBeth Capital on Monday, November 14 to “Hold”. The stock of Impax Laboratories Inc (NASDAQ:IPXL) has “Neutral” rating given on Wednesday, December 28 by Janney Capital. The rating was downgraded by Bank of America on Monday, November 7 to “Underperform”.

North Tide Capital Llc holds 4.53% of its portfolio in Impax Laboratories Inc for 2.00 million shares. Hound Partners Llc owns 4.44 million shares or 1.42% of their US portfolio. Moreover, Sector Gamma As has 1.24% invested in the company for 499,153 shares. The California-based Lyon Street Capital Llc has invested 0.69% in the stock. Sivik Global Healthcare Llc, a Connecticut-based fund reported 105,000 shares.

Analysts await Impax Laboratories Inc (NASDAQ:IPXL) to report earnings on August, 9 before the open. They expect $0.14 EPS, down 33.33% or $0.07 from last year’s $0.21 per share. IPXL’s profit will be $10.35M for 29.46 P/E if the $0.14 EPS becomes a reality. After $0.11 actual EPS reported by Impax Laboratories Inc for the previous quarter, Wall Street now forecasts 27.27% EPS growth.